Saturday 17 October 2026
Export ATNM’s income statement to Excel — free account
Actinium Pharmaceuticals, Inc.
ATNM Healthcare Biotechnology
Actinium Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $90,000.00, up 11.1% from fiscal 2023. In the quarter to June 2026, revenue grew 77,677.8%, EPS grew 504.6% and free cash flow fell 4.91%, each against the same quarter a year earlier.
1.13
0.07
+6.60%
Follow ATNM
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 45.86% | (167.66%) | (166.96%) | (133.09%) |
+8 more TTM periods Free account |
|
| 21.92% | (41.15%) | (52.67%) | (50.05%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
38.75% | (64.87%) | (81.25%) | (72.45%) | |
Average Days of Receivables |
0.00 | — | — | 0.00 | |
Free Cash Flow per Share |
(0.74) | (0.74) | (0.79) | (0.80) | |
Free Cash Flow |
(23.25) | (22.98) | (24.68) | (25.04) | |
Capital Expenditures |
(0.58) | (0.11) | (0.10) | — | |
| Other line items | |||||
Cash ROIC |
(34.81%) | (51.72%) | (44.21%) | (37.28%) | |
Accounts Receivable Turnover |
0.00 | — | — | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
51.58% | 0.00% | 0.00% | 12,021.11% | |
Selling, General and Administrative Expense of Revenue |
21.09% | 0.00% | 0.00% | 8,772.22% | |
Share Based Compensation of Revenue |
0.71% | 0.00% | 0.00% | 5,768.33% | |
Operating CF/Net income |
(2.00) | 0.97 | 0.73 | 0.72 | |
Depreciation/Fixed assets |
1.25 | 3.12 | 2.78 | 3.62 | |
Capex/Depreciation |
(0.67) | (0.13) | (0.13) | 0.00 | |
Revenue per Share |
1.12 | 0.00 | 0.00 | 0.01 | |
Operating CF per Share |
(0.72) | (0.73) | (0.79) | (0.80) | |
Capex per Share |
(0.02) | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.00 | 0.00 | 0.00 |
Columns are period end dates